Table 1 Baseline clinical characteristics of the study population
mrEF | rEF | |||||
|---|---|---|---|---|---|---|
β-blocker ( +) (n = 163) | β-blocker ( −) (n = 153) | p value | β-blocker ( +) (n = 99) | β-blocker ( −) (n = 102) | p value | |
Age (years) | 64.9 ± 12.1 | 65.7 ± 10.8 | 0.567 | 66.6 ± 10.6 | 67.8 ± 11.3 | 0.435 |
Men (%) | 137 (84.1) | 125 (81.7) | 0.579 | 84 (84.9) | 88 (86.3) | 0.774 |
BMI, (kg/m2) | 24.1 ± 4.0 | 23.1 ± 3.5 | 0.015 | 24.2 ± 4.0 | 23.2 ± 4.0 | 0.082 |
Hypertension, n (%) | 114 (69.9) | 96 (62.8) | 0.176 | 76 (76.8) | 60 (58.8) | 0.007 |
Diabetes mellitus, n (%) | 76 (46.6) | 69 (45.1) | 0.785 | 53 (53.5) | 51 (50.0) | 0.616 |
CKD, n (%) | 58 (36.5) | 51 (33.6) | 0.589 | 42 (43.3) | 50 (51.0) | 0.280 |
eGFR, (mL/min/1.73 m2) | 68.7 ± 27.7 | 66.6 ± 24.9 | 0.489 | 63.6 ± 24.6 | 60.0 ± 38.5 | 0.427 |
Family history of IHD, n (%) | 47 (29.2) | 36 (23.5) | 0.255 | 28 (28.6) | 21 (20.6) | 0.189 |
Current smoking, n (%) | 43 (26.4) | 41 (26.8) | 0.933 | 21 (21.2) | 20 (19.6) | 0.778 |
Hemoglobin, g/dL | 14.5 ± 1.3 | 13.2 ± 2.1 | 0.319 | 13.2 ± 1.8 | 12.6 ± 2.1 | 0.131 |
LDL-C, mg/dL | 111.1 ± 32.3 | 115.2 ± 31.5 | 0.249 | 114.9 ± 38.1 | 115.0 ± 37.8 | 0.983 |
HDL-C, mg/dL | 44.8 ± 14.3 | 44.7 ± 14.6 | 0.983 | 41.2 ± 10.7 | 41.5 ± 12.8 | 0.867 |
Triglycerides, mg/dL | 131.3 ± 71.6 | 121.9 ± 74.1 | 0.251 | 117.8 ± 58.3 | 117.5 ± 65.8 | 0.974 |
Systolic BP, mmHg | 135.6 ± 25.6 | 132.7 ± 21.9 | 0.289 | 124.7 ± 23.1 | 120.1 ± 21.0 | 0.143 |
Diastolic BP, mmHg | 74.6 ± 15.3 | 73.2 ± 13.9 | 0.401 | 72.2 ± 13.1 | 65.8 ± 11.9 | < 0.001 |
LVEF, % | 44.5 ± 3.1 | 44.5 ± 2.9 | 0.972 | 30.6 ± 6.8 | 30.3 ± 7.4 | 0.755 |
Multivessel disease, n (%) | 99 (61.9) | 92 (60.1) | 0.752 | 66 (66.7) | 79 (77.5) | 0.088 |
LMT lesion, n (%) | 2 (1.2) | 7 (4.6) | 0.074 | 6 (6.1) | 2 (2.0) | 0.137 |
LAD lesion, n (%) | 86 (52.8) | 72 (47.1) | 0.311 | 47 (47.5) | 52 (51.0) | 0.619 |
MLD at baseline, (mm) | 0.3 (0.3–0.4) | 0.4 (0.3–0.5) | 0.184 | 0.3 (0.2–0.4) | 0.4 (0.3–0.5) | 0.036 |
MLD post-procedure, (mm) | 2.7 (2.6–2.8) | 2.7 (2.6–2.8) | 0.708 | 2.7 (2.6–2.8) | 2.5 (2.3–2.7) | 0.062 |
Reference lumen diameter, (mm) | 2.9 (2.8–3.0) | 3.0 (2.9–3.1) | 0.053 | 2.9 (2.8–3.0) | 3.0 (2.8–3.1) | 0.379 |
Type B2/ C lesion, n (%) | 121 (74.2) | 102 (66.7.0) | 0.140 | 80 (80.8) | 58 (56.9) | < 0.001 |
Stent size, (mm) | 3.0 (3.0–3.25) | 3.0 (3.0–3.25) | 0.579 | 3.0 (2.75–3.0) | 3.0 (2.75–3.0) | 0.780 |
BMS | 86 (52.8) | 72 (47.1) | 0.311 | 40 (40.4) | 46 (45.1) | 0.569 |
DES | 48 (29.5) | 46 (30.1) | 0.905 | 37 (37.4) | 18 (17.7) | 0.003 |
ACS, n (%) | 75 (46.0) | 67 (43.8) | 0.692 | 42 (42.4) | 47 (46.1) | 0.602 |
Medications | ||||||
Aspirin, n (%) | 153 (93.9) | 139 (90.9) | 0.312 | 97 (98.0) | 79 (77.5) | < 0.001 |
Ca-blockers, n (%) | 36 (22.1) | 34 (22.2) | 0.977 | 19 (19.2) | 19 (18.6) | 0.919 |
ACE-Is/ARBs, n (%) | 117 (71.8) | 104 (68.0) | 0.556 | 70 (70.7) | 55 (53.9) | 0.014 |
Statins, n (%) | 101 (62.0) | 73 (47.7) | 0.011 | 62 (62.6) | 36 (35.3) | < 0.001 |